PITTSBURGH — Mylan had sales of $1.72 billion in fourth-quarter 2012 and $6.8 billion for fiscal year 2012, the generic drug maker said.
Those figures compared with $1.53 billion in fourth-quarter 2011 and $6.13 billion for fiscal year 2011.
The latest sales figures include $1.58 billion in generics sales and $155.1 million in branded drug sales.
"2012 was an outstanding year for Mylan, with top-line growth of 11% and bottom-line growth of 27% versus last year," Mylan CEO Heather Bresch said.
CFO John Sheehan said the company anticipated further double-digit bottom-line growth in 2013, expecting revenues of between $7 billion and $7.4 billion.
"We believe that our ability to continue to generate consistent growth underscores the power of our global platform," Sheehan said.